Identification of Chagas disease biomarkers using untargeted metabolomics.
Biomarkers
Chagas disease
Chronic chagasic cardiomyopathy
Untargeted metabolomics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 08 2024
13 08 2024
Historique:
received:
25
06
2024
accepted:
01
08
2024
medline:
14
8
2024
pubmed:
14
8
2024
entrez:
13
8
2024
Statut:
epublish
Résumé
Untargeted metabolomic analysis is a powerful tool used for the discovery of novel biomarkers. Chagas disease (CD), caused by Trypanosoma cruzi, is a neglected tropical disease that affects 6-7 million people with approximately 30% developing cardiac manifestations. The most significant clinical challenge lies in its long latency period after acute infection, and the lack of surrogate markers to predict disease progression or cure. In this cross-sectional study, we analyzed sera from 120 individuals divided into four groups: 31 indeterminate CD, 41 chronic chagasic cardiomyopathy (CCC), 18 Latin Americans with other cardiomyopathies and 30 healthy volunteers. Using a high-throughput panel of 986 metabolites, we identified three distinct profiles among individuals with cardiomyopathy, indeterminate CD and healthy volunteers. After a more stringent analysis, we identified some potential biomarkers. Among peptides, phenylacetylglutamine and fibrinopeptide B (1-13) exhibited an increasing trend from controls to ICD and CCC. Conversely, reduced levels of bilirubin and biliverdin alongside elevated urobilin correlated with disease progression. Finally, elevated levels of cystathionine, phenol glucuronide and vanillactate among amino acids distinguished CCC individuals from ICD and controls. Our novel exploratory study using metabolomics identified potential biomarker candidates, either alone or in combination that if confirmed, can be translated into clinical practice.
Identifiants
pubmed: 39138245
doi: 10.1038/s41598-024-69205-w
pii: 10.1038/s41598-024-69205-w
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18768Subventions
Organisme : Proyectos de investigación en salud, Instituto Carlos III, Ministry of Science, Innovation and Universities, Spanish Government
ID : PI19/01807
Informations de copyright
© 2024. The Author(s).
Références
Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec 90, 33–43 (2015).
Pérez-Molina, J. A. & Molina, I. Chagas disease. Lancet 391, 82–94 (2018).
doi: 10.1016/S0140-6736(17)31612-4
pubmed: 28673423
Maron, B. J. et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113, 1807–1816 (2006).
doi: 10.1161/CIRCULATIONAHA.106.174287
pubmed: 16567565
Sales, P. A. et al. Experimental and clinical treatment of chagas disease: A review. Am. J. Trop Med. Hyg. 97, 1289–1303 (2017).
doi: 10.4269/ajtmh.16-0761
Crespillo-Andújar, C. et al. Use of benznidazole to treat chronic Chagas disease: An updated systematic review with a meta-analysis. PLoS Negl. Trop Dis. 16, e0010386 (2022).
doi: 10.1371/journal.pntd.0010386
pubmed: 35576215
pmcid: 9135346
Sguassero, Y. et al. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A systematic review of follow-up Studies. PLoS One https://doi.org/10.1371/journal.pone.0139363 (2015).
doi: 10.1371/journal.pone.0139363
pubmed: 26436678
pmcid: 4593559
Castelli, F. A. et al. Metabolomics for personalized medicine: the input of analytical chemistry from biomarker discovery to point-of-care tests. Anal. Bioanal. Chem. 414, 759–789 (2022).
doi: 10.1007/s00216-021-03586-z
pubmed: 34432105
Di Minno, A., Gelzo, M., Stornaiuolo, M., Ruoppolo, M. & Castaldo, G. The evolving landscape of untargeted metabolomics. Nutr. Metab. Cardiovasc. Dis. 31, 1645–1652 (2021).
doi: 10.1016/j.numecd.2021.01.008
pubmed: 33895079
Gironès, N. et al. Global metabolomic profiling of acute myocarditis caused by Trypanosoma cruzi infection. PLoS Negl. Trop Dis. https://doi.org/10.1371/journal.pntd.0003337 (2014).
doi: 10.1371/journal.pntd.0003337
pubmed: 25412247
pmcid: 4239010
Díaz, M. L. et al. Metabolomic Profiling of End-Stage Heart Failure Secondary to Chronic Chagas Cardiomyopathy. Int. J. Mol. Sci. https://doi.org/10.3390/ijms231810456 (2022).
doi: 10.3390/ijms231810456
pubmed: 36613813
pmcid: 9735967
Echeverría, L. E. et al. Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy. PLoS One https://doi.org/10.1371/journal.pone.0258622 (2021).
doi: 10.1371/journal.pone.0258622
pubmed: 34710112
pmcid: 8553084
Chow, S. L. et al. Role of biomarkers for the prevention, assessment, and management of heart failure: A scientific statement from the American heart association. Circulation 135, e1054–e1091 (2017).
doi: 10.1161/CIR.0000000000000490
pubmed: 28446515
Shen, L. et al. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circ. Heart Fail https://doi.org/10.1161/CIRCHEARTFAILURE.117.004361 (2017).
doi: 10.1161/CIRCHEARTFAILURE.117.004361
pubmed: 29141857
Saraiva, R. M. et al. Chagas heart disease: An overview of diagnosis, manifestations, treatment, and care. World J. Cardiol. 13, 654–675 (2021).
doi: 10.4330/wjc.v13.i12.654
pubmed: 35070110
pmcid: 8716970
Linhares-Lacerda, L. et al. Circulating plasma microRNA-208a as potential biomarker of chronic indeterminate phase of chagas disease. Front Microbiol. https://doi.org/10.3389/fmicb.2018.00269 (2018).
doi: 10.3389/fmicb.2018.00269
pubmed: 29559958
pmcid: 5845676
Wu, G. Amino acids: metabolism, functions, and nutrition. Amino Acids 37, 1–17 (2009).
doi: 10.1007/s00726-009-0269-0
pubmed: 19301095
Nemet, I. et al. A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors. Cell 180, 862-877.e22 (2020).
doi: 10.1016/j.cell.2020.02.016
pubmed: 32142679
pmcid: 7402401
Romano, K. A. et al. Gut microbiota-generated Phenylacetylglutamine and heart failure. Circ. Heart Fail 16, E009972 (2023).
doi: 10.1161/CIRCHEARTFAILURE.122.009972
pubmed: 36524472
Tang, H. Y. et al. Characteristic of metabolic status in heart failure and its impact in outcome perspective. Metabolites 10, 1–14 (2020).
doi: 10.3390/metabo10110437
Velasquez-Martinez, M. C., Santos-Vera, B., Velez-Hernandez, M. E., Vazquez-Torres, R. & Jimenez-Rivera, C. A. Alpha-1 Adrenergic Receptors Modulate Glutamate and GABA Neurotransmission onto Ventral Tegmental Dopamine Neurons during Cocaine Sensitization. Int. J. Mol. Sci. https://doi.org/10.3390/ijms21030790 (2020).
doi: 10.3390/ijms21030790
pubmed: 31991781
pmcid: 7036981
Fu, H., Kong, B., Zhu, J., Huang, H. & Shuai, W. Phenylacetylglutamine increases the susceptibility of ventricular arrhythmias in heart failure mice by exacerbated activation of the TLR4/AKT/mTOR signaling pathway. Int. Immunopharmacol. 116, 109795 (2023).
doi: 10.1016/j.intimp.2023.109795
pubmed: 36736224
Zhang, Z. et al. Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure. Front. Cardiovasc. Med. https://doi.org/10.3389/fcvm.2022.1076806 (2023).
doi: 10.3389/fcvm.2022.1076806
pubmed: 38500679
pmcid: 10773866
Riedel, T. et al. Fibrinopeptides A and B release in the process of surface fibrin formation. Blood 117, 1700–1705 (2011).
doi: 10.1182/blood-2010-08-300301
pubmed: 21106983
pmcid: 3056594
Coradin, T., Wang, K., Law, T. & Trichet, L. Type I Collagen-Fibrin Mixed Hydrogels: Preparation, Properties and Biomedical Applications. Gels 2020, Vol. 6, Page 36 6, 36 (2020).
Jennewein, C. et al. Novel aspects of fibrin(ogen) fragments during inflammation. Mol. Med. 17, 568–573 (2011).
doi: 10.2119/molmed.2010.00146
pubmed: 21210072
pmcid: 3105136
Fromentin, S. et al. Microbiome and metabolome features of the cardiometabolic disease spectrum. Nature Medicine 2022 28:2 28, 303–314 (2022).
He, W. J. et al. An untargeted metabolomics study of blood pressure: findings from the Bogalusa Heart Study. J. Hypertens 38, 1302–1311 (2020).
doi: 10.1097/HJH.0000000000002363
pubmed: 32004207
pmcid: 8805288
Fujiwara, R. et al. Systemic regulation of bilirubin homeostasis: Potential benefits of hyperbilirubinemia. Hepatology 67, 1609–1619 (2018).
doi: 10.1002/hep.29599
pubmed: 29059457
Suh, S. et al. Relationship between serum bilirubin levels and cardiovascular disease. PLoS One https://doi.org/10.1371/journal.pone.0193041 (2018).
doi: 10.1371/journal.pone.0193041
pubmed: 30571703
pmcid: 6301670
Marconi, V. C. et al. Bilirubin Is Inversely Associated With Cardiovascular Disease Among HIV-Positive and HIV-Negative Individuals in VACS (Veterans Aging Cohort Study). J. Am. Heart Assoc. https://doi.org/10.1161/JAHA.117.007792 (2018).
doi: 10.1161/JAHA.117.007792
pubmed: 29720501
pmcid: 6015337
Ozeki, M. et al. High serum bilirubin is associated with lower prevalence of peripheral arterial disease among cardiac patients. Clin. Chim. Acta 476, 60–66 (2018).
doi: 10.1016/j.cca.2017.11.013
pubmed: 29155119
Stenemo, M. et al. The metabolites urobilin and sphingomyelin (30:1) are associated with incident heart failure in the general population. ESC Heart Fail 6, 764–773 (2019).
doi: 10.1002/ehf2.12453
pubmed: 31148414
pmcid: 6676274
Lee, J. S. et al. Urea cycle dysregulation generates clinically relevant genomic and biochemical signatures. Cell 174, 1559-1570.e22 (2018).
doi: 10.1016/j.cell.2018.07.019
pubmed: 30100185
pmcid: 6225773
Musch, W., Verfaillie, L. & Decaux, G. Age-related increase in plasma urea level and decrease in fractional urea excretion: clinical application in the syndrome of inappropriate secretion of antidiuretic hormone. Clin. J. Am. Soc. Nephrol. 1, 909–914 (2006).
doi: 10.2215/CJN.00320106
pubmed: 17699306
Kondo, K. et al. H
doi: 10.1161/CIRCULATIONAHA.112.000855
pubmed: 23393010
pmcid: 3670187
Ravi, R. et al. Metabolite Signature in the Carriers of Pathogenic Genetic Variants for Cardiomyopathy: A Population-Based METSIM Study. Metabolites https://doi.org/10.3390/metabo12050437 (2022).
doi: 10.3390/metabo12050437
pubmed: 36557197
pmcid: 9785662
Metsalu, T. & Vilo, J. ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucl. Acids Res. 43, W566–W570 (2015).
doi: 10.1093/nar/gkv468
pubmed: 25969447
pmcid: 4489295